Completion of ACTIV-2 Study

ACTIV-2 研究完成

• 批准号: 10710623
• 负责人: ANGEE GREER
• 金额: $ 8253.19万
• 依托单位: PPD DEVELOPMENT LP
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-11-06 至 2024-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10710623
• 关键词: COVID-19; COVID-19 therapeutics; Clinical Research; Clinical Trials; Disease Progression; Immune response; Infrastructure; Investigation; National Institute of Allergy and Infectious Disease; Outpatients; Pharmacy facility; Reporting; SARS-CoV-2 infection; Safety; Services; Support Contracts; Therapeutic Intervention; Viral; coronavirus disease; novel therapeutics; research study; therapeutic vaccine; treatment trial

NIAID is sponsoring a clinical research study on novel therapeutics for COVID-19, which is one of the clinical studies for Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). With an existing clinical trial infrastructure and multiple support contracts to provide services related to clinical trials support, regulatory support and pharmacy support, NIAID serves as the sponsor for the COVID-19 clinical trial entitled “A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)” also known as ACTIV-2. The objective of ACTIV-2 is to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression.

NIAID正在赞助一项关于新型COVID-19治疗方法的临床研究，这是加速COVID-19治疗干预和疫苗（ACTIV）的临床研究之一。凭借现有的临床试验基础设施和多个支持合同，提供与临床试验支持、监管支持和药房支持相关的服务， NIAID是名为“A5401：适应性平台治疗试验， COVID-19门诊患者（适应COVID）”也称为ACTIV-2。ACTIV-2的目的是评估多种研究药物的安全性和有效性，这些药物旨在改变宿主对SARS-CoV-2感染的免疫反应，或直接增强病毒控制以限制疾病进展。